BioVie Inc. announced the completion of enrollment for its Phase 2 SUNRISE-PD clinical trial, which is evaluating the safety and efficacy of bezisterim (NE3107) in individuals with early-stage Parkinson's disease who have not been treated with carbidopa/levodopa. The trial enrolled 60 participants diagnosed within the past four years and aims to assess whether bezisterim can affect the progression of motor and non-motor symptoms. The study uses a hybrid, decentralized design to enhance accessibility for participants. Topline results from the SUNRISE-PD trial are expected in the first half of 2026 and have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621637) on January 08, 2026, and is solely responsible for the information contained therein.